Role of RNA binding protein with multiple splicing in acute myeloid leukemia revealed

Acute myeloid leukemia (AML) is one of the most aggressive blood cancers and is characterized by the rapid growth of immature myeloid precursor cells. It predominantly affects elderly people, and current treatment options are largely limited to chemotherapy, with a five-year survival rate of only about 30%. However, chemotherapy may fail to eliminate chemotherapy-resistant leukemia-initiating cells (LICs), which frequently leads to disease relapse. For this reason, novel therapies to eliminate LICs without compromising normal blood cell production are urgently needed.